Drug Trial Radar · NCT03407144
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Apr 9, 2018
Primary completion
Feb 12, 2027
Study completion Feb 12, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Conditions
- Hodgkin Lymphoma
Interventions
pembrolizumabBiological
2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
doxorubicinDrug
25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1) 40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2) 25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)
vinblastineDrug
6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1) 6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)
dacarbazineDrug
375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1) 375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1) 250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
cyclophosphamideDrug
500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
vincristineDrug
1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2) 1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
prednisone/prednisoloneDrug
60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2) 40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
bleomycinDrug
10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
etoposideDrug
125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
Radiotherapy (RT)Radiation
RT administered daily, dose dependent on randomization group and disease response.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in SER Participants By Risk Group (Low, High) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 8 years
Locations
93 sites in 16 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama ( Site 0023)
Birmingham, Alabama
Phoenix Childrens Hospital ( Site 0034)
Phoenix, Arizona
Arkansas Children's Hospital ( Site 0046)
Little Rock, Arkansas
Kaiser - Orange County ( Site 0084)
Anaheim, California
Kaiser Permanente ( Site 0082)
Downey, California
Kaiser - Fontana ( Site 0083)
Fontana, California
MemorialCare Health System - Long Beach Medical Center-Cherese Mari Laulhere Children's Village ( Si
Long Beach, California
Kaiser Permanente Downey Medical Center ( Site 0024)
Los Angeles, California
Kaiser Permanente - Oakland ( Site 0047)
Oakland, California
Kaiser Permanente - Roseville ( Site 0080)
Roseville, California
Kaiser Permanente - Santa Clara ( Site 0079)
Santa Clara, California
Children's Hospital - Colorado ( Site 0028)
Aurora, Colorado
Connecticut Children's Medical Center ( Site 0045)
Hartford, Connecticut
Yale Cancer Center ( Site 0061)
New Haven, Connecticut
Children's National Medical Center ( Site 0090)
Washington D.C., District of Columbia
University of Florida ( Site 0051)
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital ( Site 0048)
Hollywood, Florida
Arnold Palmer Hospital ( Site 0065)
Orlando, Florida
Children's Healthcare of Atlanta at Egleston ( Site 0033)
Atlanta, Georgia
University of Chicago ( Site 0066)
Chicago, Illinois
Riley Hospital for Children ( Site 0091)
Indianapolis, Indiana
University of Kentucky Markey Cancer Center ( Site 0057)
Lexington, Kentucky
University of Louisville-Norton Children's Hospital ( Site 0059)
Louisville, Kentucky
Johns Hopkins University ( Site 0025)
Baltimore, Maryland
Children's Hospital of Michigan ( Site 0056)
Detroit, Michigan
Karmanos Cancer Institute ( Site 0002)
Detroit, Michigan
Children's Hospitals and Clinics of Minnesota ( Site 0036)
Minneapolis, Minnesota
St. Louis Children's Hospital ( Site 0038)
St Louis, Missouri
Alliance for Childhood Diseases ( Site 0064)
Las Vegas, Nevada
Hackensack University Medical Center ( Site 0026)
Hackensack, New Jersey
Rutgers Cancer Institute of New Jersey ( Site 0027)
New Brunswick, New Jersey
Roswell Park Cancer Institute ( Site 0040)
Buffalo, New York
Cohen Children's Medical Center of New York ( Site 0052)
New Hyde Park, New York
Columbia University/Herbert Irving Cancer Center ( Site 0063)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 0060)
New York, New York
Weill Cornell Medicine ( Site 0032)
New York, New York
UNC Lineberger Comprehensive Cancer ( Site 0044)
Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center ( Site 0035)
Cincinnati, Ohio
Nationwide Children's Hospital ( Site 0037)
Columbus, Ohio
St. Francis Hospital Cancer Center ( Site 0001)
Greenville, South Carolina
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.